7 September 2025
Children are often left behind when it comes to introduction of new medicines or formulations for better clinical management and improved prognoses. Introduction of a new health product requires significant engagement and planning efforts as well as guideline development and training.
The purpose of this disease agnostic toolkit is to support countries when developing implementation plans to introduce new health products for children. It is meant to serve as a guide to be adapted to the specific health product, therapeutic area, and local contexts.
The toolkit defines a series of 10 steps to be initiated concurrently or consecutively as felt appropriate by the country leadership.
Step 1. Community and other Stakeholder Engagement Step 2. In Country Registration Step 3. Revision of National Guidelines Step 4. Planning and Budgeting Step 5. Quantification Step 6. Procurement and Supply Chain Step 7. Health care provider capacitation Step 8. Demand Creation Step 9. Pharmacovigilance Step 10. Tracking and Impact.
Access the Report
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.